Telescope Innovations Installs Korea's First Self-Driving Lab for Pharma R&D and Education
Rhea-AI Summary
Telescope Innovations (OTCQB: TELIF) completed installation of Korea's first pharmaceutical Self-Driving Lab (SDL) for the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association on December 9, 2025. The SDL was deployed only three weeks after contract signing, demonstrating rapid delivery capability. The project included on-site participation by two-time Chemistry Nobel Prize winner Prof. Barry Sharpless and was enabled by collaboration with the Acceleration Consortium and Canadian–Korean partners. Telescope says the installation will accelerate R&D workflows via automated robotics, inline analytics, and AI, and positions the company to expand SDL adoption across pharmaceutical, industrial chemistry, energy, and agricultural sectors.
Positive
- Installed Korea's first pharmaceutical SDL
- Deployment completed 3 weeks after contract signing
- On-site support from two-time Chemistry Nobel laureate Barry Sharpless
- Strengthened Canada–Korea collaboration and Acceleration Consortium ties
- Positions Telescope to expand SDLs into pharma, industrial chemistry, energy, agriculture
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TELIF declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TELIF fell 8.15% while closest peers showed limited movement: HMTXF up 0.45% and NKGN, PRVCF, SRBCF, BMNDF all flat. With no peers in the momentum scanner, the move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | SDL installation Korea | Positive | +0.0% | Completed installation of Korea’s first pharmaceutical Self-Driving Lab for KPBMA. |
| Nov 17 | SDL sale Korea | Positive | +0.3% | Announced KPBMA purchase of SDL for AI-driven R&D training hub in Seoul. |
| Nov 04 | Govt funding lithium | Positive | +0.4% | Conditionally approved for up to CAD $3.36M to advance lithium processing tech. |
| Oct 23 | Debt settlement shares | Neutral | +4.8% | Settled CAD $200,000 debt via issuance of 689,654 shares at CAD $0.29. |
| Sep 29 | Lithium carbonate demo | Positive | +14.9% | Produced battery-grade lithium carbonate at >99.9% purity from recycled waste. |
Over the past six months, positive operational and funding news has generally coincided with flat to positive price reactions, suggesting today’s negative move contrasts with prior responses to constructive announcements.
This announcement on December 9, 2025 completes delivery of Korea’s first pharmaceutical Self-Driving Lab, following the November 17, 2025 sale of an SDL to KPBMA. Earlier, on November 4, 2025, Telescope was conditionally approved for up to CAD $3.36M in government funding to advance lithium technologies, and on October 23, 2025 it executed a debt-settlement share issuance. A major technical milestone came on September 29, 2025 with production of battery-grade lithium carbonate at >99.9% purity. Together, these events depict a company advancing both automation and materials platforms.
Market Pulse Summary
This announcement highlights completion of Korea’s first pharmaceutical Self-Driving Lab, reinforcing Telescope’s ability to deploy autonomous R&D systems quickly—within three weeks of contract signing. It builds on recent milestones, including up to CAD $3.36M in government funding for lithium technologies and battery-grade lithium carbonate at >99.9% purity. Investors may watch for follow-on SDL sales, execution of funded projects, and any further equity issuance as key indicators of how this commercialization momentum translates into long-term value.
Key Terms
self-driving lab technical
inline analytics technical
closed-loop workflow technical
physical AI technical
AI-generated analysis. Not financial advice.
Rapid three-week deployment, onsite support from two-time Nobel Laureate, and deep Canada-Korea collaboration underscore accelerating commercial momentum
HIGHLIGHTS
- Telescope Innovations' installation of Korea's first Self-Driving Lab for pharmaceutical research completed just three weeks after contract signing
- Project facilitated by collaboration with the Acceleration Consortium (AC) and supported on site by two-time Chemistry Nobel Laureate Prof. Barry Sharpless
- Successful SDL delivery demonstrates Telescope's growing commercial momentum, positioning Telescope and the AC to expand SDL adoption across pharma, industrial chemistry, energy, and agriculture
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") announces the successful installation of the first pharmaceutical Self-Driving Lab ("SDL") in South Korea, delivered to the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association ("KPBMA") for its new AI-focused R&D training centre in Seoul. The installation, completed only three weeks after the purchase was finalized, highlights the Company's ability to deploy integrated robotic and analytical systems on ambitious timelines, enabled in part by the Acceleration Consortium ("AC"). Two-time Nobel Prize winner in Chemistry and Telescope Advisor, Prof. Barry Sharpless joined the team on site to mark the installation and discuss the future of chemistry R&D with KPBMA leadership.
Figure 1. Prof. Barry Sharpless and the Telescope Innovations team present the new Self-Driving Lab at the Korea Pharmaceutical and Bio-Pharmaceutical Manufacturer's Association.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8923/277414_79c37fd104dad87c_001full.jpg
A HUGE MILESTONE TOWARD PRACTICAL, AUTONOMOUS R&D
"Our work in Seoul is a huge milestone toward making autonomous R&D a practical reality for pharmaceutical innovation," said Jason Hein, Telescope CTO and a member of the scientific leadership at the Acceleration Consortium. "This installation is a tangible result of a deep, almost decade-long collaboration between universities, industry partners, and government organizations in both Canada and Korea. We're thrilled to be giving researchers the ability to explore chemical space faster and with greater precision than ever before."
SELF-DRIVING LABS EXEMPLIFY A NEW MODEL FOR PHARMACEUTICAL DEVELOPMENT
A Self-Driving Lab is an automated platform that uses robotics, inline analytics, and AI to run and optimize experiments in a continuous closed-loop workflow. By operating nonstop and adjusting parameters on the fly, it completes hundreds of experiments far faster and more consistently than manual work. SDLs can significantly speed up R&D, potentially cutting years from development timelines while significantly lowering costs. Telescope and the AC are widely recognized as world leaders in developing the most advanced Self-Driving Lab systems, with uniquely integrated platforms that enable true closed-loop, autonomous chemical experimentation. Footage of Telescope's SDL is available at: https://youtu.be/9m4F78sUdII.
FUELED BY NOBEL-PRIZE-WINNING LEADERSHIP
Telescope's Senior Scientific Advisor Prof. Barry Sharpless is the only living two-time winner of the Chemistry Nobel Prize, having shaped many of the foundational principles behind modern reaction discovery. Telescope carries this legacy forward through its Self-Driving Labs, to enable researchers to move from molecular discovery to scalable deployment with unprecedented speed, precision, and reliability.
Prof. Sharpless joined the Telescope team on site in Seoul for the SDL installation and demonstration. At the facility he offered his perspective on the milestone:
"When you make and break chemical bonds conventionally, there are too many variables to make predictions; too many by-products to move forward. AI is good at predicting trends, but it can only leap over and beyond our biases if the input is right. Providing reliable AI is the gap Telescope is addressing."
Prof. Sharpless added, "AI is only as good as the chemistry it's based on, and Telescope's chemistry is superlative. It's so exciting for me to participate in making Self-Driving Labs a reality with Jason Hein and his extraordinary team."
SUPPORTED BY CROSS-SECTOR COLLABORATION
The SDL installation is built on an impressive history of collaboration:
- Initial investments by the Canadian government into the technology behind Self-Driving Labs (2018, 2023) catalyzed SDL research in Canada
- Telescope's academic roots as a spin-off from the University of British Columbia enabled early collaborations with the world's most prestigious universities and strategic industry partners
- CTO Jason Hein's leadership in the Acceleration Consortium (a network of academia, industry, and government bodies dedicated to accelerating SDL deployment), directly led to the connection between KPBMA and Telescope, catalyzing the global commercialization of accelerated scientific discovery
- Telescope's participation in B.C Premier David Eby's trade mission to Korea earlier this year solidified relationships between Canadian and Korean partners, aligning Telescope's efforts with government priorities
- Proven demand from Korea's pharmaceutical industry highlights the commercial value of Telescope's technology
"This milestone signals exactly the kind of global impact that emerges when industry and academia innovate together," said Sean Caffrey, Executive Director of the Acceleration Consortium (AC). "Through the AC, we're building a commercialization pathway that speeds up the translation of research into deployable technology. The sale of this self-driving lab is emblematic of the strides that we can make worldwide by bringing intelligent automation directly into the hands of researchers developing the pharmaceuticals we need the most."
This successful installation marks a pivotal milestone for Telescope, reinforcing the Company's ability to deploy advanced autonomous R&D systems at speed. Building on this achievement, Telescope will continue expanding its commercial opportunities in pharmaceutical research while opening new pathways in industrial chemistry, energy, and agriculture — sectors where Self-Driving Labs are emerging as one of the most compelling real-world examples of Physical AI.
About Telescope Innovations
Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
About the Acceleration Consortium
Based at the University of Toronto (U of T), the Acceleration Consortium (AC) is a global community of academia, industry, not-for-profits, and government that is accelerating the discovery of materials and molecules needed for a sustainable future. We build self-driving labs (SDLs) that use AI and automation to reduce the time and cost of bringing materials to market, such as life-saving medications, renewable energy, and biodegradable plastics. We also evaluate the economic, ethical, and social dimensions of discovery, learning from Indigenous and community-based experts to guide our materials and technologies toward the benefit of society and the planet.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: henry.dubina@telescopeinn.com
Forward-Looking Information
Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.
Forward-looking statements in this document include statements regarding the Company's expectations regarding future deployments of Self-Driving Labs; the expected benefits of Self-Driving Labs; anticipated market expansion across pharmaceutical and other industrial sectors; expected benefits of ongoing collaborations such as with the Acceleration Consortium; the Company's strategic growth and commercialization plans , and all other statements that are not statements of historical fact.
The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277414
FAQ
What did Telescope (TELIF) install in Korea on December 9, 2025?
How long did Telescope take to deploy the SDL for KPBMA (TELIF)?
Did any notable scientific leaders attend the TELIF SDL installation in Seoul?
What capabilities does the Self-Driving Lab installed by TELIF provide?
How does the Korea SDL affect Telescope's commercial plans (TELIF)?
